From Dual FDA approvals to WHO recognition, Chinese Biotech firm makes great breakthrough in cancer diagnosis.

A Historic Breakthrough!

Hymon® Pan-Cancer Screening Test Kit Secures FDA’s Second Global Pan-Cancer Early Screening “Breakthrough Device Designation”

From Dual FDA approvals to WHO recognition, Chinese Biotech firm makes great breakthrough in cancer diagnosis.

A Chinese biotechnology company has achieved two significant international milestones within a month, reflecting the growing global presence of China’s medical technology sector. Suzhou-based HymonBio has announced that one of its cancer screening technologies has received the U.S. Food and Drug Administration (FDA) Breakthrough Device Designation, while a separate diagnostic product has been selected to participate in an international evaluation programme led by the World Health Organization (WHO) and several major global health organisations.

Although the two developments focus on very different diseases, together they demonstrate the increasing importance of molecular diagnostics in tackling both chronic illnesses such as cancer and emerging infectious diseases.

AFastTrackforCancerDetection

The first announcement concerns HymonBio’s Hymon® Pan-Cancer Screening Test Kit, which was granted FDA Breakthrough Device Designation.

Pan-cancer screening represents one of the most ambitious areas of modern medicine. Rather than testing for a single type of cancer, researchers aim to detect biological signals associated with multiple cancers using a single blood sample. Early diagnosis is widely recognised as one of the most effective ways of improving survival, as many cancers become far more difficult to treat once they have spread.

HymonBio’s product is only the second pan-cancer early screening technology worldwide to receive this designation. The first was awarded to a U.S. company more than seven years ago for their NGS product. Not only is HymonBio the first and currently the only overseas company to receive the FDA Breakthrough Device Designation for a pan-cancer early screening technology, but their technique can also shorten the entire process from approximately 1 month (with the NGS method) to just 7 hours, without sacrificing any precision. In fact, it is even more accurate. This is achieved by combining modern machine learning with the traditional biotech PCR method.

RespondingtoGlobalHealthEmergencies

Only weeks later, the company announced another achievement with a very different public health focus.

HymonBio’s molecular diagnostic reagent for the Ebola virus has been selected as a candidate for an international performance evaluation programme organised by the WHO, Africa CDC, PATH, FIND, and Unitaid. The initiative aims to identify reliable diagnostic tools that can be used during Ebola outbreaks in regions where rapid and accurate testing is essential.

The announcement comes amid an ongoing outbreak of Bundibugyo virus disease, a form of Ebola affecting the Democratic Republic of the Congo and Uganda. International agencies have intensified research efforts, including clinical trials for new treatments and improvements to diagnostic capacity, recognising that early detection plays a crucial role in containing outbreaks.

Unlike many infectious diseases, Ebola can spread rapidly in healthcare settings if infected patients are not identified quickly. Reliable molecular diagnostic tests therefore form a critical part of outbreak response, allowing health authorities to isolate patients, trace contacts and begin treatment as early as possible.

（Dr Miao Tan Founder of Hymonbio, pictured while attending the Human Genome Meeting in Singapore.）

TwoDifferentDiseases,OneCommonTechnology

Although cancer and Ebola appear unrelated, both developments rely on the same underlying scientific discipline: molecular diagnostics.

Instead of detecting visible symptoms, molecular diagnostic tests identify tiny fragments of genetic material or other molecular biomarkers associated with disease. Advances in technologies such as polymerase chain reaction (PCR), DNA methylation analysis and genomic sequencing have made it possible to detect diseases earlier and with greater precision than ever before.

This growing field is transforming healthcare by enabling doctors to diagnose diseases before symptoms become severe, monitor patients more effectively and develop increasingly personalised treatments.

（Dr Miao Tan, Founder of Hymonbio, visiting Cairo University and its affiliated hospital in Cairo, Egypt.）

China’sExpandingRoleinBiotechnology

The announcements also reflect the broader internationalisation of China’s biotechnology industry.

Over the past decade, Chinese companies have increased investment in research and development while seeking validation through international regulatory agencies and global public health partnerships. Recognition from organisations such as the FDA and WHO is often viewed as an important step because it places products under internationally recognised standards for scientific evaluation. The achievements reflect China’s transition from being known primarily for manufacturing to becoming an important contributor to cutting-edge biotechnology.

Together, both achievements suggest that the company is becoming an increasingly visible participant in global medical innovation. “Our goal is to make high-tech products affordable to everyone, so that more people can benefit from them,” said Dr Tan, the founder of HymonBio.

As healthcare systems continue to face challenges ranging from cancer to emerging infectious diseases, advances in diagnostic technology are expected to remain central to improving patient outcomes worldwide.

Feel free to adjust any heading styles or spacing further according to your publication needs.